Pittsburgh Compound-B and Alzheimer’s Disease Biomarkers in CSF, Plasma and Urine: An Exploratory Study
2010 (English)In: Dementia and Geriatric Cognitive Disorders, ISSN 1420-8008, E-ISSN 1421-9824, Vol. 29, no 3, 204-212 p.Article in journal (Refereed) Published
Background: The positron emission tomography (PET) radiotracer Pittsburgh Compound-B (PIB) is an in vivo ligand for measuring β-amyloid (Aβ) load. Associations between PET PIB and cerebrospinal fluid (CSF) Aβ1–42 and apolipoprotein E ε4 (APOE ε4) have been observed in several studies, but the relations between PIB uptake and other biomarkers of Alzheimer’s disease (AD) are less investigated. Method: PET PIB, PET 18Fluoro-2-deoxy-D-glucose and different AD biomarkers were measured twice in CSF, plasma and urine 12 months apart in 10 patients with a clinical diagnosis of mild to moderate AD. Results: PIB retention was constant over 1 year, inversely related to low CSF Aβ1–42 (p = 0.01) and correlated positively to the numbers of the APOE ε4 allele (0, 1 or 2) (p = 0.02). There was a relation between mean PIB retention and CSF ApoE protein (r = –0.59, p = 0.07), and plasma cystatin C (r = –0.56, p = 0.09). Conclusion: PIB retention is strongly related to CSF Aβ1–42, and to the numbers of the APOE ε4 allele.
Place, publisher, year, edition, pages
Basel: Karger AG , 2010. Vol. 29, no 3, 204-212 p.
Pittsburgh Compound-B, PET FDG, Alzheimer’s disease, follow-up, Biomarkers, CSF, Aβ1–42, Aβx-42 APOE, Cystatin C
Research subject Psychology
IdentifiersURN: urn:nbn:se:su:diva-47144DOI: 10.1159/000281832ISI: 000276783100003PubMedID: 20332638OAI: oai:DiVA.org:su-47144DiVA: diva2:373146
authorCount :112010-11-302010-11-302010-12-22Bibliographically approved